Clinical Trials Logo

Communicable Diseases clinical trials

View clinical trials related to Communicable Diseases.

Filter by:
  • Available  
  • Page 1

NCT ID: NCT06433128 Available - Clinical trials for Invasive Fungal Infections

Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections

Start date: n/a
Phase:
Study type: Expanded Access

The EAP is intended to provide a treatment option for patients with proven or probable serious or life-threatening invasive fungal infection (in accordance with the EORTC-MSGERC criteria) who have exhausted their treatment options, primarily due to an infection with a resistant fungal pathogen, and for whom no other treatment options are available through marketed drugs or investigational agents in clinical studies ongoing in the respective indication.

NCT ID: NCT05897294 Available - Clinical trials for Invasive Pulmonary Aspergillosis

Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis

Start date: n/a
Phase:
Study type: Expanded Access

Voriconazole Inhalation Powder is available on an expanded access basis to patients with pulmonary aspergillosis for up to 12 weeks. Duration of treatment may be extended on a case-by-case basis depending on drug availability and after discussion with the Sponsor.

NCT ID: NCT04682834 Available - Clinical trials for Acute Pyelonephritis

Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection

Start date: n/a
Phase:
Study type: Expanded Access

Sulopenem etzadroxil/probenecid is available to clinicians through an Expanded Access Program for the treatment of complicated urinary tract infections due to quinolone nonsusceptible uropathogens after an initial course of effective intravenous therapy. The investigational product may be requested by sending an email to the Sponsor (EAProgram@iterumtx.com), as listed on the Reagan Udall EAP Navigator website (https://navigator.reaganudall.org/company-directory/i).

NCT ID: NCT03786900 Available - Clinical trials for Recurrent Clostridium Difficile Infection

Fecal Microbiota Transplantation (FMT): PRIM-DJ2727

Start date: n/a
Phase:
Study type: Expanded Access

The Fecal Microbiota Transplantation (FMT) product PRIM-DJ2727 is prepared from human stool from a healthy, screened donor. Requestors will contact the study team about the product (PRIM-DJ2727) by email, visit, or phone call. A screening list for donors will be provided to make sure that the list fits the requestor's requirements. A basic fee will be requested to recover the cost of making the product. After an agreement is made, a contract will be signed between the 2 parties. A week before the treatment, requestors will contact the study team for possible FMT product delivery. Delivery method will be confirmed for delivery by personnel (within 10 minutes driving distance) or by using FedEx services. Each delivered product will have an approved delivery form signed and dated by both the person who prepared the delivery and the person who received the package.